MCID: IDP011
MIFTS: 60

Idiopathic Interstitial Pneumonia

Categories: Respiratory diseases

Aliases & Classifications for Idiopathic Interstitial Pneumonia

MalaCards integrated aliases for Idiopathic Interstitial Pneumonia:

Name: Idiopathic Interstitial Pneumonia 12 15
Idiopathic Interstitial Pneumonias 37 73
Pulmonary Fibrosis 44 73
Idiopathic Interstitial Pneumonia, Not Otherwise Specified 73
Diffuse Idiopathic Pulmonary Fibrosis 12
Idiopathic Fibrosing Alveolitis 12
Hamman-Rich Syndrome 73
Ipf 12

Classifications:



Summaries for Idiopathic Interstitial Pneumonia

Disease Ontology : 12 A pneumonia located in the lung parenchyma of unknown cause.

MalaCards based summary : Idiopathic Interstitial Pneumonia, also known as idiopathic interstitial pneumonias, is related to nonspecific interstitial pneumonia and desquamative interstitial pneumonia, and has symptoms including coughing, hemoptysis and snoring. An important gene associated with Idiopathic Interstitial Pneumonia is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Bosentan and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include the lung parenchyma of unknown cause, lung and testes, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung... more...

Related Diseases for Idiopathic Interstitial Pneumonia

Diseases related to Idiopathic Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 nonspecific interstitial pneumonia 33.8 CCL2 IFNG IL13 SFTPC
2 desquamative interstitial pneumonia 33.4 MUC5B SFTPC
3 acute interstitial pneumonia 32.7 SFTPA1 SFTPA2 SFTPD
4 interstitial lung disease 30.7 CCL2 CXCL8 EDN1 IFNG IL4 MUC5B
5 connective tissue disease 30.4 EDN1 IFNG SFTPD TLR9
6 respiratory failure 30.1 CXCL8 ELANE SFTPC SFTPD
7 pneumonia 30.1 CCL2 CXCL8 ELANE IL13 MUC5B SFTPC
8 bronchiolitis 29.7 CXCL8 IFNG IL13 IL4 MUC5B TLR9
9 pulmonary hypertension 29.3 EDN1 ELANE SERPINE1 SFTPC VEGFA
10 pulmonary disease, chronic obstructive 29.1 CCL2 CXCL8 ELANE IL13 SFTPD TGFB1
11 vascular disease 28.6 CCL2 EDN1 ICAM1 SERPINE1 VEGFA
12 vasculitis 28.4 CCL2 ELANE ICAM1
13 pulmonary fibrosis, idiopathic 28.3 CCL2 CTGF CXCL8 EDN1 ELANE IFNG
14 pulmonary fibrosis 28.0 CCL2 CTGF EDN1 IL13 MUC5B SFTPA1
15 lung disease 26.9 CCL2 CXCL8 EDN1 ELANE IL13 MUC5B
16 airway-centered interstitial fibrosis 11.2
17 lymphoid interstitial pneumonia 11.1
18 cryptogenic organizing pneumonia 11.1
19 mycoplasmal pneumonia 11.0 IFNG IL4
20 respiratory distress syndrome in premature infants 10.9 SFTPA1 SFTPC
21 strongyloidiasis 10.9 IFNG IL13 TGFB1
22 penicillin allergy 10.8 IFNG IL13 IL4
23 urinary schistosomiasis 10.8 IFNG IL13 IL4
24 hyperlucent lung 10.8 IFNG IL4
25 pulmonary eosinophilia 10.8 IL13 IL4 SFTPD
26 parasitic helminthiasis infectious disease 10.7 IL13 IL4 TLR9
27 coccidiosis 10.7 IFNG IL4 TLR9
28 cryptococcosis 10.7 IFNG IL4 TLR9
29 clonorchiasis 10.7 CXCL8 IFNG TGFB1
30 food allergy 10.7 IFNG IL13 IL4
31 ocular cicatricial pemphigoid 10.7 CTGF IL4 TGFB1
32 opportunistic mycosis 10.7 IFNG IL4 TLR9
33 middle ear disease 10.7 CXCL8 MUC5B TLR9
34 ige responsiveness, atopic 10.7 IFNG IL13 IL4
35 allergic bronchopulmonary aspergillosis 10.7 IL4 SFTPA2 SFTPD
36 schistosomiasis 10.7 IFNG IL13 IL4
37 tungiasis 10.7 CXCL8 IL4
38 brucellosis 10.6 CXCL8 IFNG IL4
39 primary bacterial infectious disease 10.6 IFNG IL4 TLR9
40 toxoplasmosis 10.6 IFNG IL4 TLR9
41 pulmonary alveolar proteinosis 10.6 CCL2 SFTPC SFTPD
42 malignant renovascular hypertension 10.6 EDN1 SERPINE1
43 extrinsic cardiomyopathy 10.6 CCL2 IL4 TLR9
44 nephrosclerosis 10.6 CCL2 CTGF TGFB1
45 surfactant dysfunction 10.6 SFTPA1 SFTPC
46 leukoregulin 10.6 CXCL8 TGFB1
47 eales disease 10.6 IFNG IL4 VEGFA
48 neuritis 10.6 CCL2 IFNG IL4
49 sezary's disease 10.6 IFNG IL4 TLR9
50 vitreoretinopathy, neovascular inflammatory 10.6 CCL2 CTGF TGFB1

Comorbidity relations with Idiopathic Interstitial Pneumonia via Phenotypic Disease Network (PDN): (show all 22)


Acute Cystitis Aortic Valve Disease 1
Bronchiectasis Bronchitis
Bronchopneumonia Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Osteoporosis
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Respiratory Failure
Rheumatoid Arthritis Rheumatoid Lung Disease

Graphical network of the top 20 diseases related to Idiopathic Interstitial Pneumonia:



Diseases related to Idiopathic Interstitial Pneumonia

Symptoms & Phenotypes for Idiopathic Interstitial Pneumonia

UMLS symptoms related to Idiopathic Interstitial Pneumonia:


coughing, hemoptysis, snoring

MGI Mouse Phenotypes related to Idiopathic Interstitial Pneumonia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 IL13 SERPINE1 ICAM1 EDN1 IL4 IFNG
2 growth/size/body region MP:0005378 10.32 CXCR4 IL13 SERPINE1 ICAM1 EDN1 IL4
3 cellular MP:0005384 10.28 MUC5B GREM1 IL13 CXCR4 ICAM1 IL4
4 immune system MP:0005387 10.28 IL13 SERPINE1 ICAM1 IL4 SFTPA1 CCL2
5 hematopoietic system MP:0005397 10.27 CXCR4 IL13 SERPINE1 ICAM1 IL4 IFNG
6 mortality/aging MP:0010768 10.25 SERPINE1 ICAM1 IL4 EDN1 SFTPA1 IFNG
7 digestive/alimentary MP:0005381 10.21 CXCR4 IL13 ICAM1 EDN1 IL4 IFNG
8 endocrine/exocrine gland MP:0005379 10.15 IL13 CXCR4 ICAM1 EDN1 IL4 CTGF
9 craniofacial MP:0005382 10.07 CXCR4 EDN1 IL4 CTGF IFNG VEGFA
10 integument MP:0010771 10.02 IL13 CXCR4 SERPINE1 ICAM1 IL4 CTGF
11 neoplasm MP:0002006 9.86 CXCR4 SERPINE1 ICAM1 IFNG ELANE TGFB1
12 renal/urinary system MP:0005367 9.81 CXCR4 SERPINE1 EDN1 IL4 IFNG GREM1
13 respiratory system MP:0005388 9.77 SERPINE1 IL4 SFTPA1 IFNG CTGF MUC5B
14 skeleton MP:0005390 9.28 GREM1 IL13 CXCR4 EDN1 IL4 CTGF

Drugs & Therapeutics for Idiopathic Interstitial Pneumonia

Drugs for Idiopathic Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2 147536-97-8 104865
2
Pirfenidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53179-13-8 40632
3
Nintedanib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 656247-17-5 56843413
4
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
5 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2
6 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
7 Sildenafil Citrate Phase 4,Phase 3,Phase 2 171599-83-0
8 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
18
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
19
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
20
Acetylcysteine Approved, Investigational Phase 3,Phase 2,Phase 1 616-91-1 12035
21
Azathioprine Approved Phase 3,Phase 1,Phase 2,Not Applicable 446-86-6 2265
22
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
24
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
26
Angiotensin II Approved, Investigational Phase 2, Phase 3,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
27
Losartan Approved Phase 2, Phase 3,Not Applicable 114798-26-4 3961
28
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
31
Lenograstim Approved, Investigational Phase 3 135968-09-1
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
33
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
34
Sulfamethoxazole Approved Phase 3 723-46-6 5329
35
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
36
Warfarin Approved Phase 3 81-81-2 6691 54678486
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
39 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Platelet Aggregation Inhibitors Phase 2, Phase 3
42 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
43 Antiviral Agents Phase 3,Phase 2,Phase 1
44 Antidotes Phase 3,Phase 2,Phase 1
45 Antioxidants Phase 3,Phase 2,Phase 1
46 Expectorants Phase 3,Phase 2,Phase 1
47 N-monoacetylcystine Phase 3,Phase 2,Phase 1
48 Protective Agents Phase 3,Phase 2,Phase 1
49 Respiratory System Agents Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 314)
# Name Status NCT ID Phase Drugs
1 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
2 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
5 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Completed NCT02788474 Phase 4 nintedanib;placebo
6 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
7 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination Completed NCT02606877 Phase 4 nintedanib;pirfenidone
8 Digital Auscultation Test - IPF Data Collection Recruiting NCT03503188 Phase 4
9 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
10 Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Withdrawn NCT00625079 Phase 4 sildenafil
11 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Withdrawn NCT00625469 Phase 4 bosentan
12 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
13 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
14 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
15 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
16 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
17 Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Completed NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
18 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
19 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
20 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
21 Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Completed NCT00981747 Phase 2, Phase 3 Sildenafil;Losartan;Sildenafil and Losartan;Placebo pill
22 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
23 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
24 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
25 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
26 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
27 A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00047645 Phase 3 Interferon-gamma 1b
28 Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
29 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients Completed NCT01335464 Phase 3 placebo;BIBF 1120
30 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II Completed NCT01335477 Phase 3 placebo;BIBF 1120
31 Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Completed NCT02584816 Phase 3
32 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Completed NCT00650091 Phase 3 N-acetylcysteine (NAC);Placebo
33 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients Completed NCT01014442 Phase 3 mycophenolate mofetil
34 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
35 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
36 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
37 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
38 Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02739165 Phase 3 ART-123;Placebo
39 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Recruiting NCT03208933 Phase 3 Pirfenidone
40 Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
41 Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea Recruiting NCT03018756 Phase 3 Fentanyl Citrate;Placebo
42 CleanUP IPF for the Pulmonary Trials Cooperative Recruiting NCT02759120 Phase 3 Antimicrobial therapy: Co-trimoxazole or Doxycycline
43 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT01619085 Phase 3 BIBF 1120
44 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Active, not recruiting NCT02597933 Phase 3 Nintedanib;Placebo
45 Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis Not yet recruiting NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids
46 Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole Terminated NCT01777737 Phase 3 Cotrimoxazole;Placebo
47 ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Terminated NCT00879229 Phase 3 Ambrisentan;Placebo
48 AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Terminated NCT00957242 Phase 3 warfarin;placebo
49 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
50 The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Terminated NCT00075998 Phase 3 Interferon gamma-1b ("Actimmune")

Search NIH Clinical Center for Idiopathic Interstitial Pneumonia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pulmonary fibrosis

Genetic Tests for Idiopathic Interstitial Pneumonia

Anatomical Context for Idiopathic Interstitial Pneumonia

The Foundational Model of Anatomy Ontology organs/tissues related to Idiopathic Interstitial Pneumonia:

19
The Lung Parenchyma Of Unknown Cause

MalaCards organs/tissues related to Idiopathic Interstitial Pneumonia:

41
Lung, Testes, Bone Marrow, Bone, Heart, Skin, Liver

Publications for Idiopathic Interstitial Pneumonia

Articles related to Idiopathic Interstitial Pneumonia:

(show top 50) (show all 155)
# Title Authors Year
1
A Serological Biomarker of Versican Degradation is Associated with Mortality Following Acute Exacerbations of Idiopathic Interstitial Pneumonia. ( 29728109 )
2018
2
Idiopathic Interstitial Pneumonia as a Possible Cause of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Report. ( 29901014 )
2018
3
Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF). ( 29496758 )
2018
4
Cardiorespiratory adaptation in a 6-minute walk test by fibrotic idiopathic interstitial pneumonia patients who did or did not respond to pulmonary rehabilitation. ( 29904044 )
2018
5
Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients. ( 29900176 )
2018
6
Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. ( 28300570 )
2017
7
Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. ( 29229096 )
2017
8
Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease. ( 29038933 )
2017
9
Respiratory bronchiolitis-associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. ( 28523329 )
2017
10
Occupational and Environmental Risk Factors for Chronic Fibrosing idiopathic Interstitial Pneumonia in South Korea. ( 28938261 )
2017
11
Impact of lymphocyte differential counta88>a8815% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. ( 28427425 )
2017
12
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. ( 28838377 )
2017
13
Baseline serum syndecan-4 predicts prognosis after the onset of acute exacerbation of idiopathic interstitial pneumonia. ( 28467516 )
2017
14
Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-Melanoma Differentiation-Associated Gene-5 Antibody by Intensive Immunosuppressive Therapy. ( 29269659 )
2017
15
Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection. ( 27277761 )
2016
16
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. ( 26792595 )
2016
17
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? ( 27884593 )
2016
18
The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. ( 27757985 )
2016
19
Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. ( 26792177 )
2016
20
Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. ( 27287654 )
2016
21
Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis. ( 27564852 )
2016
22
Idiopathic pleuroparenchymal fibroelastosis - A rare idiopathic interstitial pneumonia. ( 27141432 )
2016
23
Increased erythrocyte aggregation and oxidative stress in patients with idiopathic interstitial pneumonia. ( 28079842 )
2016
24
Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias. ( 26873743 )
2016
25
Identification of Clinical Phenotypes in Idiopathic Interstitial Pneumonia with Pulmonary Emphysema. ( 27301501 )
2016
26
A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. ( 26932342 )
2016
27
Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. ( 27460223 )
2016
28
Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report. ( 26810762 )
2016
29
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. ( 27266705 )
2016
30
Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. ( 26699835 )
2016
31
Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. ( 26116477 )
2015
32
Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. ( 26416262 )
2015
33
Evolving Early Lung Cancers Detected During Follow-Up of Idiopathic Interstitial Pneumonia: Serial CT Features. ( 26001227 )
2015
34
Increased ectodomain shedding of cell adhesion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia. ( 26231557 )
2015
35
Broader criteria of undifferentiated connective tissue disease in idiopathic interstitial pneumonias. ( 25682542 )
2015
36
Idiopathic interstitial pneumonia in the ICU: an observational cohort. ( 26603794 )
2015
37
SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. ( 26568241 )
2015
38
Scoring of the radiological picture of idiopathic interstitial pneumonia: a study to verify the reliability of the method. ( 26600944 )
2015
39
Symptom-based management of the idiopathic interstitial pneumonia. ( 26450007 )
2015
40
Newly Detected Pulmonary Nontuberculous Mycobacterial Infection and Peripheral Lung Cancers in Patients During Follow-Up of Idiopathic Interstitial Pneumonia: Comparison of CT Findings. ( 25837763 )
2015
41
Role of I+1 and I+2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts. ( 26006016 )
2015
42
The correlation of symptoms, pulmonary function tests and exercise testing with high-resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in South India. ( 26664164 )
2015
43
Smoking-related idiopathic interstitial pneumonia: A review. ( 26138798 )
2015
44
Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs. ( 26539479 )
2015
45
Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients. ( 24613046 )
2014
46
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability. ( 24886036 )
2014
47
Low-normal lung volume correlates with pulmonary hypertension in fibrotic idiopathic interstitial pneumonia: computer-aided 3D quantitative analysis of chest CT. ( 25055292 )
2014
48
Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. ( 24480141 )
2014
49
Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. ( 24388373 )
2014
50
Smoking-related idiopathic interstitial pneumonia. ( 25063244 )
2014

Variations for Idiopathic Interstitial Pneumonia

Expression for Idiopathic Interstitial Pneumonia

Search GEO for disease gene expression data for Idiopathic Interstitial Pneumonia.

Pathways for Idiopathic Interstitial Pneumonia

Pathways related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CCL2 CXCL8 ELANE ICAM1 IFNG IL13
2
Show member pathways
13.5 CCL2 CTGF CXCL8 CXCR4 IFNG IL13
3
Show member pathways
13.42 CCL2 CTGF CXCL8 CXCR4 IL13 IL4
4
Show member pathways
13.37 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
5
Show member pathways
13.3 CCL2 CTGF CXCL8 CXCR4 IL13 IL4
6
Show member pathways
13 CCL2 CXCL8 IFNG SERPINE1 SFTPA2 SFTPD
7
Show member pathways
12.88 CXCL8 CXCR4 ICAM1 IFNG IL13 IL4
8 12.85 CXCL8 CXCR4 IFNG IL13 IL4 TGFB1
9
Show member pathways
12.8 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
10 12.57 CCL2 CXCR4 IFNG IL4 TLR9
11
Show member pathways
12.43 IFNG IL13 IL4 TGFB1
12
Show member pathways
12.34 CCL2 ICAM1 IFNG IL4 SERPINE1
13
Show member pathways
12.33 CCL2 CXCL8 IFNG IL13 IL4 MUC5B
14 12.25 CTGF GREM1 SERPINE1 TGFB1
15
Show member pathways
12.23 CXCL8 EDN1 MUC5B SERPINE1
16 12.2 IFNG TGFB1 TLR9 VEGFA
17
Show member pathways
12.15 CXCL8 IFNG IL4 SFTPA1 SFTPD TLR9
18 12.12 CCL2 EDN1 ICAM1 IFNG VEGFA
19 11.99 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
20
Show member pathways
11.98 CCL2 CTGF CXCL8 ICAM1 IFNG IL13
21 11.96 CXCL8 IFNG SERPINE1 TGFB1
22 11.93 EDN1 IFNG SERPINE1 VEGFA
23
Show member pathways
11.89 SFTPA1 SFTPA2 SFTPC SFTPD
24
Show member pathways
11.86 CXCL8 ICAM1 TGFB1
25 11.86 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
26 11.83 CCL2 GREM1 TGFB1
27 11.81 CXCL8 ICAM1 IFNG IL13 IL4
28 11.78 IFNG IL13 IL4
29
Show member pathways
11.76 CXCL8 IFNG IL4
30 11.76 CXCL8 SFTPA1 SFTPA2
31 11.75 CCL2 CXCL8 ICAM1 IFNG TGFB1 VEGFA
32 11.74 IFNG TGFB1 TLR9
33 11.71 CXCR4 EDN1 SERPINE1 VEGFA
34
Show member pathways
11.69 CXCL8 ICAM1 IFNG VEGFA
35 11.63 IFNG SERPINE1 TGFB1
36 11.57 CXCL8 TGFB1 VEGFA
37 11.54 CTGF ELANE ICAM1
38
Show member pathways
11.51 SFTPA1 SFTPA2 SFTPD
39 11.51 IFNG IL13 IL4
40 11.5 CCL2 CXCL8 EDN1 ICAM1 SERPINE1 TGFB1
41 11.49 CXCL8 ICAM1 IFNG
42
Show member pathways
11.49 SFTPA1 SFTPA2 SFTPC SFTPD
43 11.49 CCL2 CXCL8 ICAM1 IL13 IL4
44 11.4 EDN1 SERPINE1 VEGFA
45 11.37 ICAM1 IFNG TLR9
46 11.33 IFNG IL13 IL4
47 11.32 CCL2 CXCL8 ICAM1 IFNG TGFB1 TLR9
48 11.29 IFNG IL13 IL4 TGFB1
49 11.27 IFNG IL13 TGFB1
50 11.22 IFNG IL13 IL4

GO Terms for Idiopathic Interstitial Pneumonia

Cellular components related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCL2 CTGF CXCL8 EDN1 ELANE GREM1
2 cell surface GO:0009986 9.85 CXCR4 ELANE GREM1 ICAM1 TGFB1 VEGFA
3 collagen trimer GO:0005581 9.63 SFTPA1 SFTPA2 SFTPD
4 platelet alpha granule lumen GO:0031093 9.61 SERPINE1 TGFB1 VEGFA
5 extracellular space GO:0005615 9.6 CCL2 CTGF CXCL8 EDN1 ELANE GREM1
6 rough endoplasmic reticulum GO:0005791 9.58 SFTPA1 SFTPA2 SFTPD
7 clathrin-coated endocytic vesicle GO:0045334 9.56 SFTPA1 SFTPA2 SFTPC SFTPD
8 multivesicular body GO:0005771 9.5 SFTPA1 SFTPA2 SFTPD
9 lamellar body GO:0042599 9.46 SFTPA1 SFTPA2 SFTPC SFTPD

Biological processes related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 CCL2 CTGF ICAM1 TGFB1
2 negative regulation of gene expression GO:0010629 9.98 CTGF IFNG TGFB1 VEGFA
3 cellular protein metabolic process GO:0044267 9.98 SFTPA1 SFTPA2 SFTPC SFTPD
4 positive regulation of protein phosphorylation GO:0001934 9.94 CTGF IFNG TGFB1 VEGFA
5 positive regulation of angiogenesis GO:0045766 9.93 CXCL8 GREM1 SERPINE1 VEGFA
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 GREM1 ICAM1 TGFB1 TLR9
7 cellular response to lipopolysaccharide GO:0071222 9.9 CCL2 CXCL8 ICAM1 SERPINE1
8 cellular response to interferon-gamma GO:0071346 9.88 CCL2 EDN1 ICAM1
9 response to lipopolysaccharide GO:0032496 9.88 CXCL8 EDN1 ELANE ICAM1 IL13
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 ICAM1 TGFB1 VEGFA
11 cellular response to tumor necrosis factor GO:0071356 9.87 CCL2 CXCL8 EDN1 ICAM1
12 chemokine-mediated signaling pathway GO:0070098 9.85 CCL2 CXCL8 CXCR4
13 neutrophil chemotaxis GO:0030593 9.85 CCL2 CXCL8 EDN1
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL13 VEGFA
15 response to hypoxia GO:0001666 9.85 CXCR4 EDN1 ICAM1 TGFB1 VEGFA
16 angiogenesis GO:0001525 9.85 CCL2 CTGF CXCL8 GREM1 SERPINE1 VEGFA
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 EDN1 ELANE IL13
18 calcium-mediated signaling GO:0019722 9.83 CXCL8 CXCR4 EDN1
19 positive regulation of B cell proliferation GO:0030890 9.8 IL13 IL4 TLR9
20 cellular response to interleukin-1 GO:0071347 9.8 CCL2 CXCL8 EDN1 ICAM1
21 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 EDN1 ICAM1 IFNG
23 developmental process GO:0032502 9.77 SFTPA1 SFTPA2 SFTPD
24 response to amino acid GO:0043200 9.76 CTGF EDN1 ICAM1
25 positive regulation of phagocytosis GO:0050766 9.75 SFTPA1 SFTPA2 SFTPD
26 positive regulation of MAP kinase activity GO:0043406 9.73 EDN1 ELANE TGFB1 VEGFA
27 induction of positive chemotaxis GO:0050930 9.71 CXCL8 VEGFA
28 positive regulation of protein complex assembly GO:0031334 9.71 IFNG TGFB1 VEGFA
29 toll-like receptor signaling pathway GO:0002224 9.71 SFTPA1 SFTPA2 SFTPD TLR9
30 response to molecule of bacterial origin GO:0002237 9.7 CXCL8 TLR9
31 macrophage chemotaxis GO:0048246 9.7 CCL2 SFTPD
32 positive regulation of cardiac muscle cell differentiation GO:2000727 9.7 GREM1 TGFB1
33 PERK-mediated unfolded protein response GO:0036499 9.69 CCL2 CXCL8
34 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.69 GREM1 TGFB1 VEGFA
35 negative regulation of interleukin-17 production GO:0032700 9.68 IFNG TGFB1
36 acute inflammatory response to antigenic stimulus GO:0002438 9.67 ELANE ICAM1
37 positive regulation of immunoglobulin production GO:0002639 9.66 IL13 TLR9
38 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.64 GREM1 VEGFA
39 response to salt GO:1902074 9.63 EDN1 TGFB1
40 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 ICAM1 IL13 IL4 SERPINE1
41 positive regulation of odontogenesis GO:0042482 9.61 EDN1 TGFB1
42 negative regulation of complement-dependent cytotoxicity GO:1903660 9.55 IL13 IL4
43 surfactant homeostasis GO:0043129 9.46 SFTPA1 SFTPA2 SFTPD VEGFA
44 respiratory gaseous exchange GO:0007585 9.35 EDN1 SFTPA1 SFTPA2 SFTPC SFTPD
45 regulation of signaling receptor activity GO:0010469 9.32 CCL2 CTGF CXCL8 EDN1 IFNG IL13
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 EDN1 GREM1 IL4 SERPINE1 TGFB1 TLR9
47 immune response GO:0006955 10.09 CCL2 CXCL8 IFNG IL13 IL4
48 positive regulation of gene expression GO:0010628 10.04 CTGF IFNG TGFB1 TLR9 VEGFA
49 positive regulation of cell proliferation GO:0008284 10.03 CTGF EDN1 GREM1 IFNG TGFB1 VEGFA
50 inflammatory response GO:0006954 10 CCL2 CXCL8 CXCR4 IL13 TGFB1 TLR9

Molecular functions related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 CTGF IL4 TGFB1 VEGFA
2 lipopolysaccharide binding GO:0001530 9.43 SFTPA1 SFTPA2 SFTPD
3 vascular endothelial growth factor receptor 2 binding GO:0043184 9.37 GREM1 VEGFA
4 cytokine activity GO:0005125 9.28 CCL2 CXCL8 EDN1 GREM1 IFNG IL13
5 monosaccharide binding GO:0048029 9.13 SFTPA1 SFTPA2 SFTPD
6 protein binding GO:0005515 10.13 CCL2 CTGF CXCL8 CXCR4 EDN1 ELANE

Sources for Idiopathic Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....